Publications
-
Alpha-Thalassemia: A Practical Overview
α-Thalassemia is an inherited blood disorder characterized by decreased synthesis of α-globin chains that results in an imbalance of α and β globin and thus varying degrees of ineffective erythropoiesis, decreased red blood cell (RBC)…
Read More » -
The Italian Breakthrough in CRISPR trials for Rare Diseases: A focus on β-Thalassemia and Sickle Cell Disease Treatment
The development of gene therapy and the current advantageous method of clustered regularly interspaced short palindromic repeats (CRISPRs) has allowed the implementation of several clinical trials aimed at studying the…
Read More » -
LentiGlobin Administration to Sickle Cell Disease Patients: Effect on Serum Markers and Vaso-Occlusive Crisis
LentiGlobin, an innovative gene therapy, introduces a modified beta-globin gene that yields an anti-sickling hemoglobin variant. It boosts total hemoglobin levels, mitigates hemolysis, curtails inflammation, and addresses iron overload by…
Read More » -
‘Phenoconversion’ in Adult Patients with β-Thalassemia
Rate and risk factors for phenoconversion from non-transfusion-dependent β-thalassemia (NTDT) to transfusion-dependent β-thalassemia (TDT) during a 10-year follow up of adult patients in Italy.
Read More » -
Pregnancy Outcomes and Iron Status in β-Thalassemia Major and Intermedia: A Systematic Review and Meta-analysis
Advancements in orally bioavailable iron chelators and MRI methods have improved life expectancy and reproductive potential in Thalassemia Major (TM) and Thalassemia Intermedia(TI). Pregnancy is associated with adverse maternal and…
Read More » -
A Cross-Sectional, Multicenter, Disease-Specific, Health-Related Quality of Life study in Greek Transfusion Dependent Thalassemia Patients
The assessment of Health-Related Quality of Life (HRQoL) in Thalassemia offers a holistic approach to the disease and facilitates better communication between physicians and patients. This study aimed to evaluate…
Read More » -
Economic and Clinical Burden of Managing Transfusion-Dependent b-Thalassemia in the United States
Aims To describe clinical complications, treatment use, healthcare resource utilization (HCRU), and costs among patients with transfusion-dependent β-thalassemia (TDT) in the United States. Materials and methods Merative MarketScan Databases were…
Read More » -
Erythropoiesis in Lower-risk Myelodysplastic Syndromes and Beta Thalassemia
The hematologic disorders myelodysplastic syndromes and beta-thalassemia are characterized by ineffective erythropoiesis and anemia, often managed with regular blood transfusions. Erythropoiesis, the process by which sufficient numbers of functional erythrocytes are produced from hematopoietic…
Read More » -
Association of Osteoporosis and Sarcopenia with Fracture Risk in Transfusion-Dependent Thalassemia
Patients with transfusion-dependent thalassaemia (TDT) have an increased risk of osteoporosis and fractures. They also have several potential factors associated with sarcopenia. There has been currently no study on sarcopenia…
Read More » -
Lung Function Decline in Children with Sickle Cell Disease Treated with Hydroxyurea
Sickle cell disease (SCD), the most common form of an inherited hematological disorder, is caused by a genetic variant that leads to the synthesis of an abnormal haemoglobin, HbS. Deoxygenated…
Read More »